Tag Archives: ATBPF
Analysts Offer Insights on Healthcare Companies: Antibe Therapeutics (Other OTC: ATBPF), Cortexyme (NASDAQ: CRTX) and Immunovant (NASDAQ: IMVT)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Antibe Therapeutics (ATBPF – Research Report), Cortexyme (CRTX – Research Report) and Immunovant (IMVT – Research Report) with bullish sentiments. Antibe Therapeutics
Analysts Are Bullish on Top Healthcare Stocks: Antibe Therapeutics (ATBPF), Agenus (AGEN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antibe Therapeutics (ATBPF – Research Report) and Agenus (AGEN – Research Report) with bullish sentiments. Antibe Therapeutics (ATBPF) In a report issued
Antibe Therapeutics (ATBPF) Gets a Buy Rating from Brookline Capital Markets
Brookline Capital Markets analyst Sally Yanchus maintained a Buy rating on Antibe Therapeutics (ATBPF – Research Report) on December 1 and set a price target of $20.60. The company’s shares closed last Thursday at $3.18. According to TipRanks.com, Yanchus is
The Chief Executive Officer of Antibe Therapeutics (Other OTC: ATBPF) is Buying Shares
Today, the Chief Executive Officer of Antibe Therapeutics (ATBPF – Research Report), Daniel Marcel Legault, bought shares of ATBPF for $25.5K. This recent transaction increases Daniel Marcel Legault’s holding in the company by 13% to a total of $170.6K. In
The Chief Scientific Officer of Antibe Therapeutics (Other OTC: ATBPF) is Buying Shares
Yesterday, the Chief Scientific Officer of Antibe Therapeutics (ATBPF – Research Report), John Lawrence Wallace, bought shares of ATBPF for $26.46K. This recent transaction increases John Lawrence Wallace’s holding in the company by 11% to a total of $190.1K. In
The Divisional Senior Vice-President of Antibe Therapeutics (Other OTC: ATBPF) is Buying Shares
Yesterday, the Divisional Senior Vice-President of Antibe Therapeutics (ATBPF – Research Report), Rami Batal, bought shares of ATBPF for $10.14K. This recent transaction increases Rami Batal’s holding in the company by 15% to a total of $53.29K. In addition to
